



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/55, 9/22, 15/62, C07K 19/00,</b> <b>16/46, A61K 38/46</b>	<b>A1</b>	<b>(11) International Publication Number: WO 99/46389</b> <b>(43) International Publication Date: 16 September 1999 (16.09.99)</b>
<b>(21) International Application Number:</b> PCT/US99/04252 <b>(22) International Filing Date:</b> 11 March 1999 (11.03.99)  <b>(30) Priority Data:</b> 60/077,557 11 March 1998 (11.03.98) US  <b>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application</b> US 60/077,557 (CIP) Filed on 11 March 1998 (11.03.98)  <b>(71) Applicant (for all designated States except US):</b> IMMUNOMEDICS, INC. [US/US]; 300 American Road, Morris Plains, NJ 07950 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> GOLDENBERG, David, M. [US/US]; 330 Pleasant Valley Road, Mendham, NJ 07945 (US). HANSEN, Hans [US/US]; 133 North Burgee Drive, Little Egg Harbor, NJ 08087 (US). LEUNG, Shui-on [-/US]; 254 Kings Road, Madison, NJ 07940 (US).	<b>(74) Agents:</b> SAXE, Bernhard, D. et al.; Foley & Lardner, Suite 500, 3000 K Street, N.W., Washington, DC 20007-5109 (US).  <b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(54) Title:</b> RECOMBINANT ONCONASE, AND CHEMICAL CONJUGATES AND FUSION PROTEINS OF RECOMBINANT ONCONASE		
<b>(57) Abstract</b>		
<p>Recombinantly-produced Onconase molecules and fusion proteins containing the same are disclosed. The recombinantly-produced Onconase molecule has the sequence of native Onconase, retains the proper folding of native Onconase and has cytotoxic activity similar to that of Onconase purified from oocytes of <i>Rana pipiens</i>. cDNA coding for Onconase is extended by one triplet which codes for N-formyl-methionine. When expressed recombinantly, the mutant Onconase has N-formyl-methionine as the N-terminal amino acid, and glutaminyl as the penultimate N-terminal residue. Following expression, the N-formyl methionine residue is cleaved and the penultimate glutaminyl residues are cyclized to produce Onconase with an N-terminal pyroglutamate residue, and hence the same structure and function as native Onconase.</p>	<pre> 50 ATGCAGGATT GGCTAACGTT TCAGAAGAAA CATATCACGA ATACACGAGA TACGTCCTAA CCGATTGCAA AGTCTTCTTT GTATAGTGCT TATCTGCTCT M Q D W L T F Q K K H I T N T K D  100 TGTAGACTGC GACAAATATA TGTCTACGAA TCTGTTTCAC TGTAAGGATA ACATCTGACG CTGTTATATT ACAGATGCTT AGACAAAGTG ACATTCCTAT V D C D N I M S T N L F H C K D  150 AGAATACCTT TATATACAGT CGGCCAGAGC CTGTAAGGC TATCTGTAAA TCTTATGGAA ATATATGTCA GCCGGTCTCG GACATTTCCG ATAGACATTT K N T F I Y S R P E P V K A I C K  200 GGCATTATCG CGAGTAAGAA CGTGCTGACT ACTTCCGAGT TCTATCTGTC CCGTAATAGC GCTCATTCTT GCACGACTGA TGAAGGCTCA AGATAGACAG G I I A S K N V L T T S E F Y L S  250 CGATTGCAAT GTGACTTCAC GGCCTTGCAA ATATAAGCTG AAGAAAAGCA GCTAACGTTA CACTGAAGTG CCGGGACGTT TATATTCGAC TTCTTTTCGT D C N V T S R P C K Y K L K K S  300 CTAACAAATT TTGCGTAACT TGCGAGAACC AGGCTCTGT ACATTTCGTT GATTGTTTAA AACGCATTGA ACGCTCTTGG TCCGAGGACA TGTAAGCAA T N K F C V T C B N Q A P V H F V  GGAGTCGGGA GCTGCTAA CCTACGCCCT CGACGATT G V G S C *</pre>	

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

RECOMBINANT ONCONASE, AND CHEMICAL CONJUGATES  
AND FUSION PROTEINS OF RECOMBINANT ONCONASE

Background of the Invention

5       The present invention relates to  
recombinantly-produced Onconase molecules and fusion  
proteins containing the same.

Onconase is a non-mammalian ribonuclease  
(RNase) with a molecular weight of 12,000 that is  
purified from *Rana pipiens* oocytes and early  
10       embryos. Onconase causes potent inhibition of  
protein synthesis in the rabbit reticulocyte lysate  
(IC<sub>50</sub> 10<sup>-11</sup> M) and when microinjected into *Xenopus*  
oocytes (IC<sub>50</sub> 10<sup>-10</sup> M). Unlike other members of the  
RNase A superfamily, Onconase does not degrade  
15       oocyte rRNA. Upon binding to the cell surface  
receptors of sensitive cells and its cytosolic  
internalization, Onconase causes cell death as a  
result of potent protein synthesis inhibition by a  
mechanism involving inactivation of cellular RNA.  
20       Onconase is not inhibited by mammalian placental  
ribonuclease inhibitor and this may explain  
Onconase's enhanced cytotoxicity when compared to  
the mammalian enzymes.

Animal toxicology studies show that Onconase  
25       displays a predictable, dose-dependent and  
reversible toxicity in both rats (dose range  
0.01-0.02 mg/kg) and dogs (0.005-0.15 mg/kg). Mice  
inoculated with the aggressive M109 Madison lung  
carcinoma and treated with both daily and weekly  
30       schedule of intraperitoneally-administered Onconase,

showed significantly prolonged survival. Most striking results were seen in a group of mice treated with a weekly schedule of Onconase in which six of eighteen animals survived long-term and were  
5 apparently cured of cancer.

Onconase has been shown in clinical trials to have anti-tumor activity against a variety of solid tumors. In this regard it has been used both alone and combined with other anti-tumor agents such as  
10 tamoxifen, e.g., when treating patients with pancreatic cancer. When used as an anti-tumor agent, Onconase can be conjugated to a marker which targets it to a specific cell type.

In a Phase I study, patients suffering from  
15 a variety of relapsing and resistant tumors were treated intravenously with Onconase. A dose of 60-690  $\mu\text{g}/\text{m}^2$  of Onconase resulted in the possible side effects of flushing myalgias, transient dizziness, and decreased appetite in general. The observed  
20 toxicities, including the dose-limiting renal toxicity manifested by increasing proteinuria, peripheral edema, azotemia, a decreased creatinine clearance, as well as fatigue, were dose-dependent and reversible, which is in agreement with the  
25 animal toxicology studies. No clinical manifestations of a true immunological sensitization was evident, even after repeated weekly intravenous doses of Onconase. The maximum tolerated dose, mainly due to renal toxicity, was found to be  
30 960  $\mu\text{g}/\text{m}^2$ . There were also some objective responses in non-small cell lung, esophageal, and colorectal carcinomas. Nevertheless, Onconase was well-tolerated by animals and the majority of human

patients tested, demonstrated a consistent and reversible clinical toxicity pattern, and did not induce most of the toxicities associated with most of the chemotherapeutic agents, such as  
5 myelosuppression and alopecia.

Onconase thus has many desirable characteristics, including small size, animal origin, and anti-tumor effects *in vitro* and *in vivo*. It is well-tolerated and refractory to human RNase inhibitors. However, Onconase purified from *Rana pipiens* oocytes has undesirable properties. The fact that it is obtained from a natural source makes it more difficult and expensive to obtain sufficient quantities. Since it is not derived from humans, or  
10 even mammals, it typically stimulates undesirable immune responses in humans. Accordingly, it would be advantageous recombinantly to produce native Onconase which retains the cytotoxic properties of Onconase purified from *Rana pipiens* oocytes, but  
15 does not have the undesirable immune responses in humans.

Attempts to produce native Onconase in *E. coli* by recombinant DNA methodology have failed. Onconase has an N-terminal pyroglutamyl residues  
25 which is required for proper folding of the molecule. This residue forms part of the phosphate binding pocket of Onconase, and is essential for RNase and anti-tumor activity. The initiation codon in *E. coli* inserts N-formyl-methionine in peptides  
30 as the N-terminal amino acid residue. Therefore, native Onconase recombinantly-produced in *E. coli* does not have pyroglutamyl as the N-terminal residue.

WO 97/31116 claims to have solved the problem of producing a modified Onconase that retains cytotoxic activity. It discloses a recombinant ribonuclease that has an amino terminal end beginning with a methionine followed by an amino acid other than glutamic acid, a cysteine at positions 26, 40, 58, 84, 95 and 110, a lysine at position 41, and a histidine at position 119 of bovine RNase A, and a native Onconase-derived amino acid sequence. WO 97/3116 does not recognize the importance of pyroglutamate as the N-terminal residue, and does not produce an Onconase molecule with an N-terminal pyroglutamate. To the contrary, WO 97/3116 suggests the addition of amino terminal sequences and/or fusion at the N-terminus to a ligand molecule.

#### Brief Description of the Drawing

Figure 1 shows the nucleic acid sequence and amino acid sequence of NfM-Onconase.

#### Summary of the Invention

It is an object of the present invention to provide a recombinantly-produced Onconase which retains the cytotoxic properties of Onconase, while eliminating the undesirable side effects.

It is another object of the invention to provide a recombinantly-produced Onconase which has an N-terminal pyroglutamate residue.

These and other objects according to the invention are provided by an Onconase molecule which has pyroglutamate as the N-terminal residue, wherein said Onconase molecule is recombinantly-produced in

*E. coli*. The recombinantly-produced Onconase molecule has the sequence and structure of Onconase purified from *Rana pipiens*.

5 The present invention also provides fusion proteins comprising a recombinantly-produced Onconase molecule fused to a targeting moiety. The fusion protein may be made by recombinantly expressing a nucleic acid sequence encoding Onconase and a targeting moiety. The targeting moiety may be  
10 one of an antibody, antibody fragment, cytokine and growth receptor, and preferably is a F(ab')<sub>2</sub>, F(ab)<sub>2</sub>, Fab', Fab, or Fv antibody fragment.

The present invention also provides  
15 conjugates of recombinant Onconase and a targeting moiety. The conjugates can be made by chemically coupling a recombinantly-produced Onconase molecule to a targeting moiety in a covalent linkage.

A composition comprising recombinantly-produced Onconase or chemical conjugate or fusion  
20 protein according to the invention and a pharmaceutically acceptable carrier also is provided. The compositions are useful in a method of treatment for cancer, which comprises administering to a subject in need of such treatment  
25 a therapeutically effective amount of the recombinantly-produced Onconase, chemical conjugate or fusion protein.

Other objects, features and advantages of the present invention will become apparent from the  
30 following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by

way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

5                    Description of Preferred Embodiments

                  It surprisingly has been discovered that an Onconase molecule which (1) has the sequence of native Onconase, (2) retains the proper folding of native Onconase and (3) has cytotoxic activity  
10                    similar to that of Onconase purified from oocytes of *Rana pipiens*, can produced recombinantly in *E. coli*. In accordance with the present invention, the cDNA coding for Onconase is extended by one triplet which codes for N-formyl-methionine. When expressed  
15                    recombinantly, the mutant Onconase has N-formyl-methionine as the N-terminal amino acid, and glutaminy l as the penultimate N-terminal residue. The expression product produced in accordance with the present invention is referred to herein as NfM-onconase. Following expression, the N-formyl  
20                    methionine residue is cleaved and the penultimate glutaminy l residues is cyclized to produce Onconase with an N-terminal pyroglutamate residue, referred to herein as rOnconase. rOnconase has the same  
25                    structure and function as native Onconase.

Definitions

                  Unless otherwise defined, all technical and scientific terms used have the same meaning as commonly understood by one of ordinary skill in the  
30                    art. In addition, the contents of all references cited herein are incorporated by reference in their



entirety. For purposes of the present invention, the following terms are defined as follows:

5 Amino acids are referred to by name or by either their commonly known three-letter symbols or by the one-letter IUPAC symbols. Nucleotides are referred to by their commonly accepted single-letter codes.

10 "Conservatively modified variations" of a particular nucleic acid sequence refer to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of  
15 functionally identical nucleic acids encode any given polypeptide. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to  
20 any of the corresponding codons described without altering the encoded polypeptide. Each codon in a nucleic acid except AUG which encodes methionine can be modified to yield a functionally identical molecule. The nucleic acid sequences described  
25 herein also encompass these alterations.

"Conservatively modified variations" of an amino acid sequence include individual substitutions which alter a single amino acid or a small percentage of amino acids in an encoded sequence,  
30 where the alterations result in the substitution of an amino acid with a chemically similar amino acid. Conservative substitutions are well known to those of skill in the art. The following six groups each

contain amino acids that are conservative substitutions for one another:

1. Alanine, Serine, Threonine
  2. Aspartic acid, Glutamic Acid
  - 5 3. Asparagine, Glutamine
  4. Arginine, Lysine
  5. Isoleucine, Leucine, Methionine, Valine,
- and

6. Phenylalanine, Tyrosine, Tryptophan.

10 "Conservatively modified variations" of an amino acid sequence also include deletions or additions of a single amino acid or a small percentage of amino acids in an encoded sequence, where the additions and deletions result in the

15 substitution of an amino acid with a chemically similar amino acid. The amino acid sequences described herein also encompass these variations.

The terms "isolated" or "biologically pure" refer to material which is substantially or

20 essentially free from components which normally accompany it as found in its naturally occurring environment. The isolated material optionally comprises material not found with the material in its natural environment.

25 The term "nucleic acid" refers to a deoxyribonuclease or ribonucleotide polymer in either single- or double-stranded form and, unless otherwise limited, encompasses known analogues of natural nucleotides that hybridize to nucleic acids

30 in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence includes its complementary sequence.

An "expression vector" includes a recombinant expression cassette which includes a nucleic acid which encodes a polypeptide according to the invention which can be transcribed and translated by a cell. A recombinant expression cassette is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements which permit transcription of a particular nucleic acid in a target cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the recombinant expression cassette portion of the expression vector includes a nucleic acid to be transcribed and a promoter operably linked thereto.

The term "recombinant" when used with reference to a protein indicates that a cell expresses a peptide or protein encoded by a nucleic acid whose origin is exogenous to the cell. Recombinant cells can express genes that are not found within the native (non-recombinant) form of the cell. Recombinant cells also can express genes found in the native form of the cell wherein the genes are re-introduced into the cell by artificial means, for example, under the control of a heterologous promoter.

The term "substantial identity" or "substantial similarity" in the context of a polypeptide indicates that a polypeptide comprises a sequence with at least 80%, more preferably 90%, and most preferably at least 95% identity with a reference sequence. Two polypeptides that are substantially identical means the one of the polypeptides is immunologically reactive with

antibodies raised against the second peptide. Two nucleic acids are substantially identical is the two molecules hybridize to each other under stringent conditions. Generally, stringent conditions are selected to be about 5°C to 20°C lower than the thermal melting point ( $T_m$ ) for a specific sequence at a defined ionic strength and pH. The  $T_m$  is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. However, nucleic acids which do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides they encode are substantially identical.

An "antibody" includes both whole antibodies and antibody fragments such as  $F(ab')_2$ ,  $F(ab)_2$ ,  $Fab'$ ,  $Fab$ ,  $Fv$  and the like, including hybrid fragments. Also useful are any subfragments that retain the hypervariable, antigen-binding region of an immunoglobulin.

A "targeting moiety" is an antibody, cytokine or growth factor that is specific to a marker on a given cell type. A targeting moiety can be used to specifically deliver an attached molecule to a given cell type, by preferentially associating with the marker associated with that cell type.

A "fusion protein" is a chimeric molecule formed by joining two or more polypeptides, more particularly, Onconase and a targeting moiety. Onconase and the targeting moiety are joined through a peptide bond formed between the amino terminus of the targeting moiety and the carboxyl terminus of Onconase, and are expressed recombinantly by a

nucleic acid sequence encoding the fusion protein. A single chain fusion protein is a fusion protein that has a single contiguous polypeptide backbone.

5 A "chemical conjugate" is a conjugate formed by the chemical coupling of Onconase and a targeting moiety.

"A pharmaceutically acceptable carrier" is a material that can be used as a vehicle for administering the Onconase or fusion protein because  
10 the material is inert or otherwise medically acceptable, as well as compatible with the fusion protein or armed ligand.

In accordance with the present invention, nucleic acid that encodes native Onconase may be  
15 prepared by cloning and restriction of appropriate sequences, or using DNA amplification with polymerase chain reaction (PCR). The amino acid sequence of Onconase can be obtained from Ardelt et al., *J. Biol. Chem.*, **256**: 245 (1991), and cDNA  
20 sequences encoding native Onconase, or a conservatively modified variation thereof, can be gene-synthesized by methods similar to the *en bloc* V-gene assembly in hLL2 humanization. Leung et al., *Mol. Immunol.*, **32**: 1413 (1995). For expression in  
25 *E. coli*, a translation initiation codon ATG, is placed in-frame preceding the Onconase cDNA sequence. The translated protein then contains an additional Met at the -1 position.

Alternatively, nucleic acid that encodes  
30 native Onconase may be synthesized *in vitro*. Chemical synthesis produces a single-stranded oligonucleotide. This may be converted to a double-stranded DNA by hybridization with a complementary

sequence, or by polymerization with a DNA polymerase using the single strand as a template. While chemical synthesis is limited to sequences of about 100 bases, longer sequences may be obtained by  
5 ligating shorter sequences.

As noted, a gene encoding native Onconase, or a conservatively modified variation thereof, is modified to include a codon for N-formyl-methionine at the N-terminus. The thus-obtained NfM-onconase  
10 gene is operably linked to a suitable *E. coli* promoter, such as the T7, trp, or lambda promoter, and inserted in an expression cassette. Preferably a ribosome binding site and transcription termination signal also are included in the  
15 expression cassette. An expression vector that contains the cassette is transferred into an *E. coli* expression host by methods known to those of skill in the art. Transformed cells can be selected resistance to antibiotics conferred by marker genes  
20 contained in the expression vector.

The transformed *E. coli* host expresses NfM-Onconase, which may be contained in an inclusion body. Although Onconase possesses potent RNase activity, NfM-Onconase does not. This is because  
25 the N-terminal pyroglutamate on Onconase is part of the active site, as demonstrated by the crystal structure of Onconase. The inherent nature of the bacterial expression system, which requires an N-terminal Met, means that the bacterial expression  
30 product is inactive. This enables recombinant expression of NfM-Onconase in bacterial expression systems. While NfM-Onconase is not toxic, it also may be expressed as inactive inclusion bodies.

NfM-Onconase can be isolated and purified according to standard procedures, including ammonium sulfate precipitation, affinity columns, column chromatography, and gel electrophoresis. Substantially pure compositions of at least about 90-95% homogeneity, and preferably 98-99% homogeneity, are preferred.

Following purification of the NfM-onconase, and refolding of the molecule if it was expressed in an inclusion body, the N-formyl-methionine is removed by digestion with aminopeptidase. A suitable aminopeptidase is *Aeromonas* aminopeptidase, as disclosed in Shapiro et al. *Anal. Biochem.* 175:450-461 (1988). Incubation of the resulting product results in spontaneous cyclization of the N-terminal glutamine residue, to form a molecule having the structure and function of native Onconase.

The recombinantly-produced Onconase can be used as an alternative or complement to existing toxins, as well as for construction of effective chemical conjugates and fusion proteins of high potency and low immunogenicity. In this regard, chemical conjugates and fusion proteins comprise a molecule having the structure and function of native Onconase and an antibody, antibody fragment, cytokine or growth factor. The antibody, cytokine or growth factor portion of the chemical conjugate or fusion protein is a targeting moiety, which targets the Onconase to an antigen or receptor on a particular cell type.

An exemplary antigen for targeting are glycosylated cell surface antigens that are

expressed on solid tumors, such as carcinoembryonic antigen (CEA). CEA represents an attractive antigenic target for several reasons. It is a tumor-associated antigen that it is absent or poorly expressed by normal tissues and highly expressed by the vast majority of carcinomas of breast, colon, lung, pancreatic, ovarian, and medullary thyroid origin. High mortality rates coupled with suboptimal diagnostic and therapeutic options for these malignancies result in a serious, persistent public health problem. Chemical conjugates and/or fusion proteins of Onconase and antibodies to glycosylated surface antigens, particularly anti-CEA antibodies, are preferred embodiments according to the invention.

CEA is a glycosylated cell surface protein of approximately 180 kDa, and is a solid tumor antigen that has been extensively studied clinically, both as a circulating tumor marker and as an antigenic target for radiolabeled mAbs for imaging and therapy. A number of anti-CEA antibodies have been under study in phase I-III clinical diagnostic and therapeutic trials. Exemplary of an anti-CEA mAb is the MN14 mAb. A humanized version of this mAb, hMN-14, in which human constant and framework regions replace the corresponding mouse sequences, has been constructed and expressed and is the mAb used in these clinical trials. A <sup>99m</sup>Tc-labeled Fab' fragment of another, related anti-CEA mAb, Immu-4, is useful in the detection and staging of colon cancer. Chemical conjugates and/or fusion proteins of Onconase and hMN-14 and Immu-4 represent



preferred embodiments in accordance with the present invention.

Other exemplary antigens for targeting include different B-cell restricted CD (clusters of  
5 differentiation) antigens, including CD19-22, CD37, and HLA-DR. Preferred antigens are CD20, which is expressed at a high antigen density in a wide range of B-cell malignancies, ranging from acute  
10 lymphocytic leukemia (ALL) to the more differentiated B-Cell (B-CLL) and non-Hodgkin's lymphoma (NHL), and even to hairy cell leukemia (HCL), and CD22, an efficiently internalizing antigen which is associated with virtually all non-Hodgkin's lymphomas.

15 A preferred antibody for targeting Onconase to Non-Hodgkins lymphoma is LL2 (IgG2a/kappa), a murine monoclonal antibody. Results show that LL2 is rapidly internalized after cell surface binding, with dimeric IgG or F(ab')<sub>2</sub>, exhibiting a faster rate  
20 than monomeric Fab'. The antibody appears to be degraded mainly in lysosomes, since degradation is inhibited significantly in the presence of lysosomal inhibitors such as ammonium chloride or leupeptin.

VK and VH sequences for LL2 can be cloned  
25 using PCR-amplification, using the method and primers described by Orlandi et al., *PNAS*, 86: 3833 (1989).

Suitable antibody fragments to these antigens include F(ab')<sub>2</sub>, F(ab)<sub>2</sub>, Fab', Fab, Fv and the like,  
30 including hybrid fragments. Also useful are any subfragments that retain the hypervariable, antigen-binding region of an immunoglobulin, including genetically-engineered and/or recombinant proteins,

whether single-chain or multiple-chain, which incorporate an antigen binding site and otherwise function in vivo as targeting moieties in substantially the same way as natural immunoglobulin fragments.

5 Single-chain binding molecules are disclosed in U.S. Patent 4,946,778. Fab' antibody fragments may be conveniently made by reductive cleavage of F(ab')<sub>2</sub> fragments, which themselves may be made by  
10 pepsin digestion of intact immunoglobulin. Fab antibody fragments may be made by papain digestion of intact immunoglobulin, under reducing conditions, or by cleavage of F(ab)<sub>2</sub> fragments which result from careful papain digestion of whole Ig. The fragments  
15 may also be produced by genetic engineering.

Cytokine receptors such as IL-1R, IL-2R, IL-4R, IL-6R, IL-7R, IL-9R, IL-13R and IL-15R also can be targeted by targeting moieties. In one embodiment, cytokine receptors can be targeted to the  
20 surface of cells that normally lack such receptors by the use of mAb-receptor conjugates, as described in copending application Serial No. 08/949,758, filed October 14, 1997. Receptors for growth factors like insulin and epidermal growth factor  
25 (EGF) can also be used to target rOnconase to a specific cell type.

Fusion proteins can be produced recombinantly, using the same basic methodology described above. For example, cDNA that encodes  
30 NfM-onconase can be inserted into a plasmid that also contains cDNA that encodes a single-chain antibody fragment (scFv). Because the N-terminal pyroglutamyl residue is essential for the RNAase and

cytotoxic activity of Onconase, the NfM-Onconase cDNA is inserted so that the expression product is [NfM-Onconase]-[scFv]. When Fab' is used as the fusion partner, the NfM-Onconase can extend from the N-terminal domain of either the light or heavy chain, i.e., the terminal COOH of Onconase is joined to the terminal NH<sub>2</sub> of the heavy or light chain of the Fv. Recombinantly-produced fusion proteins can be purified, the N-formyl-methionine removed and the terminal glutaminy residue cyclized to produce pyroglutamate as described above for recombinantly-produced Onconase.

Alternatively, a chemical conjugate of recombinantly-produced Onconase according to the invention and an antibody, cytokine or growth factor can be produced. The chemical conjugate can be formed by covalently linking the antibody, antibody fragment, cytokine or growth factor to the Onconase, directly or through a short or long linker moiety, through one or more functional groups on the antibody, antibody fragment, cytokine or growth factor, e.g., amine, carboxyl, phenyl, thiol or hydroxyl groups, to form a covalent conjugate. Various conventional linkers can be used, e.g., diisocyanates, diisothiocyanates, carbodiimides, bis(hydroxysuccinimide) esters, maleimide-hydroxysuccinimide esters, glutaraldehyde and the like.

Recombinantly-produced Onconase and/or chemical conjugates or fusion proteins according to the invention are formulated into pharmaceutical compositions for treating tumors or killing other unwanted cell types *in vivo*. An example of the

latter include the killing of T-cells that would cause graft-versus-host disease following organ transplantation. The compositions are particularly suitable for parenteral administration, such as  
5 intravenous administration. In this context, the compositions comprise a solution of the Onconase molecule or chemical conjugate or fusion protein dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier such as buffered  
10 saline. These solutions are sterile and may contain auxiliary substances such as pH adjusting and buffering agents and toxicity adjusting agents.

Dosage of Onconase molecule or chemical conjugate or fusion protein according to the  
15 invention is about 0.1 to 10 mg per patient per day, although dosages of up to 100 mg per patient per day may be used, particularly when the drug is administered locally, and not into the bloodstream. Like native Onconase, recombinantly-produced  
20 Onconase according to the invention is readily internalized in cells, has anti-tumor effects *in vivo*, and preferentially kills rapidly dividing tumor cells. Chemical conjugates and fusion proteins provide for more specific targeting of the  
25 recombinantly-produced Onconase to particular cells.

In therapeutic applications, compositions are administered to a patient suffering from a disease, in a cytotoxic amount, which is defined as an amount sufficient to kill cells of interest. An amount  
30 successful to accomplish this is defined as a "therapeutically effective amount." The exact amount will depend on the severity of the disease and the general state of the patient's health.

Single or multiple administrations of the compositions may be administered depending on the dosage required.

Onconase and/or chemical conjugates or fusion proteins according to the invention can also be used to treat populations of cells *in vitro*. For example, it may be used selectively to kill unwanted cell types in bone marrow prior to transplantation into a patient undergoing marrow ablation.

The following examples are illustrative of the present invention, but are not to be construed as limiting.

Example 1.                    Synthesis of PCR-amplified DNA encoding NfM-onconase

A 139-mer DNA nucleotide, ONCO-N, with the sense strand sequence [5'-TGG CTA ACG TTT CAG AAG AAA CAT ATC ACG AAT ACA CGA GAT GTA GAC TGG GAC AAT ATA ATG TCT ACG AAT CTG TTT CAC TGT AAG GAT AAG AAT ACC TTT ATA TAC AGT CGG CCA GAG CCT GTA AAG GCT ATC TGT A-3'] encoding an N-terminal sequence (46 amino acids) of recombinant Onconase is synthesized by an automated DNA synthesizer (Applied Biosystem 392 DNA/RNA Synthesizer) and used as the template for PCR-amplification with the flanking primers ONNBACK [5'-AAG CTT CAT ATG CAG GAT TGG CTA ACG TTT CAG AAG AAA-3', and ONNFOR [5'-CTT ACT CGC GAT AAT GCC TTT ACA GAT AGC CTT TAC AGG CTC TG-3']. The resultant double-stranded PCR product contains cDNA sequence that encodes for 54 amino acid residues of the N-terminal half of Onconase. ONNBACK contains the restriction sites HindIII (AAAGCTT) and NdeI (CATATG) to facilitate subcloning into either a

staging vector or for in-frame ligation (NdeI site) into the bacterial expression vector. The NruI site (TCGCGA) is incorporated in the ONNFOR primer to facilitate in-frame ligation with the cDNA encoding the C-terminal half of Onconase.

Similarly, a 137-mer DNA nucleotide, ONCO-C, with the sense-strand sequence [TGC TGA CTA CTT CCG AGT TCT ATC TGT CCG ATT GCA ATG TGA CTT CAC GGC CCT GCA AAT ATA AGC TGA AGA AAA GCA CTA ACA AAT TTT GCG TAA CTT GCG AGA ACC AGG CTC CTG TAC ATT TCG TTG GAG TCG GG-3'] encoding the C-terminal sequence (46 amino acids) of Onconase is synthesized and PCR-amplified by the primers ONCBACK[5'-ATT ATC GCG AGT AAG AAC GTG CTG ACT ACT TCC GAG TTC TAT-3'] and ONCFOR[5'-TTA GGA TCC TTA GCA GCT CCC GAC TCC AAC GAA ATG TAC-3']. The final double-stranded PCR product contained a cDNA sequence that encoded 51 amino acids of the rest of the C-terminal half of Onconase. A NruI site allowed in-frame ligation with the N-terminal half of the PCR-amplified DNA incorporated in ONCBACK. A stop codon (shown in bold italics) and BamHI restriction sites (underlined) for subcloning into staging or expression vectors were included in the ONCFOR sequence.

The PCR-amplified DNA encoding the N- and C-terminal half of NfM-Onconase, after being treated with the appropriate restriction enzymes, were joined at the NruI sites and subcloned into a staging vector, e.g., pBluescript from Stratagene. The ligated sequence should encode a polypeptide of 105 amino acids with an N-terminal Met.

Example 2.            Cloning of LL2 and MN14 V-region  
sequences and humanization of LL2  
and MN14

5            The V-region sequences of hLL2 and hMN14  
have been published. Leung et al., *Mol. Immunol.*,  
32:1413 (1995); U.S. 5,874,540. The VK and VH  
sequences for LL2 and MN14 were PCR-amplified using  
published methods and primers.

10           Sequence analysis of the PCR-amplified DNAs  
indicated that they encoded proteins typical of  
antibody VK and VH domains. A chimeric antibody  
constructed based on the PCR-amplified LL2 and MN14  
sequences exhibited immunoreactivity comparable to  
their parent antibodies, confirming the authenticity  
15           of the sequence obtained.

             Sequence analysis of the LL2 antibody  
revealed the presence of a VK-appended N-linked  
glycosylation site in the framework-1 region.  
Mutational studies indicated that glycosylation at  
20           the VK-appended site was not required to maintain  
the immunoreactivity of the antibody. Without the  
inclusion of the FR-1 glycosylation site, REI  
framework sequences were used as the scaffold for  
grafting the light chain CDRs, and EU/NEWM for  
25           grafting the heavy chain CDRs of LL2. The  
immunoreactivity of the humanized LL2 (hLL2) was  
shown to be comparable to that of murine and  
chimeric LL2. The rate of internalization for LL2  
was not affected by chimerization or humanization of  
30           the antibody.

Example 3. Construction of gene encoding fusion protein of humanized LL2 and NfM-onconase

5 The VH and VK sequences of hLL2 were used as templates to assemble the hLL2-scFv gene by standard PCR procedures. The configuration of the gene was Met(-1)-VL-(GGGS)<sub>4</sub>-VH-(His)<sub>6</sub>. A Met (ATG) initiation codon at the -1 position was incorporated at the N-terminus of the VL gene, which was linked via a 16  
10 amino acid linker (GGGS)<sub>6</sub> to the VH domain. A tail consisting of six histidyl residues was included at the carboxyl end of the VH chain to facilitate the purification of the fusion protein via metal chelate chromatography.

15 The immunotoxin fusion protein gene for NfM-Onconase-hLL2scFv was constructed in a similar fashion by restriction digestion and ligation methods. The cDNA sequence, when expressed, encoded a fusion protein of the structure:

20 NfM-Onconase-[linker]-VL-(GGGS)<sub>4</sub>-VH-(His)<sub>6</sub>.

There are a variety of linkers that can be inserted between the NfM-Onconase C-terminus and the VL domain N-terminus. A preferable linker is the amino acid sequence TRHRQPRGW from the C-terminal  
25 position 273-281 of *Pseudomonas* exotoxin (PE). This sequence has been shown to be a recognition site for intracellular cleavage of PE into active fragments by subtilisins, with cleavage occurring between the G and W residues of the sequence. Chiron et al., *J. Biol Chem.*, **269**:18167 (1994). Incorporation of this  
30 sequence facilitates the release of active rOnconase after internalization of the fusion immunotoxin. Alternatively, a 13-amino acid residue spacer



consisting of amino acid residues 48-60 of fragment B of *Staphylococcal* Protein A, used in the construction of an EDN-scFv fusion, can be used instead to allow for flexible linkage between the rOnconase and the scFv. Tai et al., *Biochemistry*, 29:8024 (1990) and Rybak et al., *Tumor Targeting*, 1:141 (1995).

Example 4. Construction of gene encoding fusion protein of humanized MN14 and NfM-Onconase

MN14 scF<sub>v</sub> was produced by PCR amplification of cDNA from humanized MN14 transfectoma. The linker used for MN14 scF<sub>v</sub> was a 15-amino acid linker (GGSGS)<sub>3</sub> and the orientation was V<sub>L</sub>-linker-V<sub>H</sub>. After confirmation of the DNA sequences, the single chain construct was subcloned into an appropriately restricted expression plasmid used for other scF<sub>v</sub>s. This construct then was transformed into BL21(λDE3) *E. coli* for expression.

Another single chain construct also was made. This was made with the opposite 5'-3' orientation of the heavy and light chains, was assembled in pCANTABE5E (Pharmacia Biotech, Piscataway, NJ) and expressed in phage. Specific binding of recombinant phage expressing this scF<sub>v</sub> was demonstrated by ELISA.

The V<sub>L</sub>-linker-V<sub>H</sub> sequence was used for construction of Onconase-MN14 fusion protein, as diagrammed below. The DNA fragment encoding Onconase was obtained according to Example 1. A 23-amino acid linker was used between the Onconase sequence and the scF<sub>v</sub>. Kurucz et al. (1995). Alternatively, the (GGSGS)<sub>3</sub> linker which was used in

construction of the MN14 scFv, described above was used. A preferred configuration of the fusion protein was:

Onconase -linker--V<sub>L</sub>-(GGSGS)<sub>3</sub>--V<sub>H</sub>

5      Example 5.      Expression and purification of hLL2-scFv, hMN14-scFv, NfM-Onconase-hLL2-scFv immunotoxin, and NfM-Onconase-hMN14-scFv immunotoxin

10      A vector for expression of hMN14-scFv and hLL2-scFv is the commercially-available T7 promoter-driven pET vector (Novagen, Madison, WI). The DNA expression vectors scFvhMN14-pET and scFvhLL2-pET are derived from pET and contain the scFv sequence for hMN14 or hLL2 fused to PE40 which was destroyed  
15      by a SalI/XhoI deletion, with a T7 promoter.

20      NfM-Onconase cDNA was digested with NdeI/BamHI and cloned into the corresponding sites in the vectors scFvhMN14-pET and scFvhLL2-pET, and the sequences were confirmed. A redundant sequence between the BamHI and the EagI site within the expression vector scFvhMN14-pET was removed by  
25      restriction digestion, gel-purification and religation. The fragment removed was found to contain part of the scFvMN14 and the defective PE40 gene. The final scFvhMN14-NfM-Onconase expression vector was further sequenced and designated rOnpET.

30      Large scale expression of the recombinant protein from the T7-driven rOnpET vector requires an appropriate host *E. coli*, such as BL21, which contains a  $\lambda$ DE3 lysogen, as described above. rOnpET vector was used to transform competent BL21/ $\lambda$ DE3 cells by electroporation. Colonies that survived selection on Amp agar plates were picked and grown

in a shaker incubator at 37°C in 3 ml of LB-Amp. After incubation for 8-10 hours, 100  $\mu$ l of the culture was transferred to 25 ml of superbrot (LB supplemented with 0.5% glucose, 1.6 mM MgSO<sub>4</sub> and 100  $\mu$ g/ml ampicillin) in a 500 ml E-flask to increase aeration while shaking. The culture was incubated overnight in the shaker incubator at 37°C. The culture then was transferred into one liter of superbrot and further incubated in a shaker incubator at 37°C. IPTG at a final concentration of 1 mM was added into the culture when the OD<sub>650</sub> of the culture reached 1 (approx. 2.5 hours). Induction was allowed to proceed for 1-3 hours before the culture was terminated for inclusion body isolation. Ten  $\mu$ l of the culture was analyzed under reducing conditions in 15% SDS-PAGE gel. Colonies with the highest level of induction were kept as stock culture and stored frozen at -70°C.

The  $\lambda$ DE3 lysogen carries the inducible T7 RNA polymerase gene. The results showed that expression of the T7 polymerase was induced by the addition of IPTG, and the expressed T7 polymerase in turn activated the transcription of the T7-driven recombinant protein. T7 promoter-driven transcription was so efficient that the protein was abundantly expressed and precipitated in the cytoplasm as inclusion bodies.

Inclusion body isolation entailed lysis of cells by homogenization in the presence of lysozymes to release the inclusion bodies as insoluble pellets. The washed inclusion bodies were dissolved in denaturing buffer that contained 7 M of guanidine-HCl. Disulfide bonds were reduced by

dithioerythritol and then were refolded by dropwise dilution of the denatured protein in renaturing buffer that contained arginine-HCL and oxidized glutathione.

5      Example 6.      Expression and purification of NfM-Onconase

          A 6-liter culture equivalent of renatured inclusion bodies from Example 5 was purified. Harvested cell paste was resuspended using a  
10      Tisuemizer tip (Thomas, Swedesboro, NJ) in TES buffer (50 mM Tris, pH 8, 100 mM NaCl, and 20 mM EDTA) containing 180 µg/ml lysozyme. After incubating at 22°C for one hours, the cells were resuspended again and centrifuged at 27,000g for 50  
15      minutes. The pellet was washed by resuspension and centrifugation three or four times with TES buffer containing 2.5% Triton-X-100 and then four times with TES. The inclusion bodies were resuspended in 5 to 10 ml of denaturation buffer (7 M  
20      guanidine:HCl, 0.1 M Tris, pH 8.0, and 5 mM EDTA) by sonication or tissuemizing and diluted to a protein concentration of 10 mg/ml.

          The protein was reduced with dithioerythritol (65 mM) for 4 to 24 hours at 22°C and rapidly  
25      diluted in a thin stream into refolding buffer (0.1 M Tris, pH 8.0, 0.5 arginine:HCl, 2 mM EDTA, and 0.9 mM oxidized glutathione). After incubating at 10°C for 36 to 72 hours, the refolded NfM-Onconase was dialyzed against 0.15 M sodium acetate  
30      (pH 5), and was loaded onto a HiLoad 16/20 SP cation exchange FPLC column. After buffer exchange into 0.15 M sodium acetate (pH 5), precipitates formed.

These were removed by centrifugation. Elution with a 0-1 M linear gradient of sodium chloride was used, and fractions corresponding to absorbance peaks were analyzed by SDS-PAGE (15%). Most column-bound  
5 proteins eluted at 0.5 M NaCl.

The eluted products were roughly divided into three fractions. Fraction I constituted the major peak. Fractions II and III were relatively minor peaks which eluted in advance of fraction I, with  
10 fraction II being a shoulder peak of fraction I.

Example 7: Removal of Met from NfM-Onconase and NfM-Onconase fusion proteins

The N-terminal Met residues of NfM-Onconase, NfM-Onconase-hMN14-scFv and NfM-Onconase-hLL2-scFv  
15 were removed according to Shapiro et al. (1988). 100-200 µg/ml of purified and renatured proteins were incubated with 0.5 µg/ml *Aeromonas proteolytica* aminopeptidase (Sigma Chemicals, St. Louis, MO) in 200 mM sodium phosphate, pH 7.5 for 18 hours at  
20 37°C.

Example 8: Preparation of antibody rOnconase conjugates

Disulfide-linked conjugates were prepared as described by Newton et al., *J. Biol. Chem.*,  
25 **267**: 19572 (1992), with some modification. 2-Iminothiolane-modified antibody was incubated overnight at 23°C with a 40-fold excess of rOnconase modified with N-succinimidyl-3-(2-pyridyldithio)-propionate (SPDP) (1.1-1.3 mol SPDP/mol rOnconase).  
30 Rybak et al., *J. Biol. Chem.*, **266**: 21202 (1991). Thioether-linked conjugates were prepared according

to standard procedures, using *m*-maleimidobenzoyl-*N*-hydroxylsuccinimide ester (MBS). Gulberg *et al.*, *Biochem. Biophys. Res. Commun.*, 139: 1239 (1986). Two separate tubes containing 2 mg of antibody were  
5 incubated with a 5-fold molar excess of MBS (stock solution, 30 mM in dimethylformamide) for 10 minutes at 23°C. The tubes were pooled and applied to a PD 10 column equilibrated with buffer A (0.1 M NaPO<sub>4</sub>, pH 7.5, containing 0.1 M NaCl). The peak fractions,  
10 each containing 1.5 ml, were pooled. Buffer A was exchanged into buffer B (0.1 M Na acetate, pH 4.5, containing 0.1 M NaCl) by repeated concentration followed by reconstitution of the recovered retentate with buffer B using Centricon 10  
15 microconcentrators (Amicon). The SPDP-modified rOnconase was reduced for 30 minutes at 23°C with 23 mM dithiothreitol and gel filtered on a PD 10 column equilibrated with buffer A. The peak fractions, about 1.5 ml each, were added to tubes  
20 containing 750 µl of MBS-modified antibody and incubated overnight at 23°C. The next day conjugates were incubated with 0.5 mM *N*-ethylmaleimide (20 mM) in dimethylformamide for at least one hour before purification by size-exclusion  
25 high-performance liquid chromatography on a TSK 3000 column (Toso Haas Corp., PA) equilibrated and eluted with 0.1 M phosphate buffer, pH 7.4. The flow rate was 0.5 ml/min and 1-minute fractions were collected. Peak fractions were pooled and analyzed  
30 by SDS-PAGE to determine the amount of free ligand and rOnconase in the conjugates.

Example 9:        *In vitro* activity of rOnconase and  
rOnconase immunotoxins

5        The ability of rOnconase to inhibit protein  
synthesis in a rabbit reticulocyte lysate was  
assessed using protocols described by St. Clair et  
*al.*, *PNAS USA*, **84**: 8330 (1987). All fractions were  
passed through Superose 12 FPLC before being tested  
for activity, however, because aminopeptidase has a  
molecular weight of 29 kD and NfM-Onconase has a  
10        molecular weight of 12 kD, the two could not be  
separated by size exclusion chromatography using  
Superose 12 FPLC. Nevertheless, results confirmed  
that rOnconase inhibited protein synthesis.

15        Native Onconase (AlfaCell), fraction I  
untreated with aminopeptidase (negative control),  
and fractions I, II and III treated with  
aminopeptidase (AP) at different molar  
concentrations were added to the *in vitro*  
translation system. <sup>32</sup>Met incorporation was measured  
20        after incubating the mixture with or without  
ribonucleases in a scintillation counter, to assess  
the rate of protein synthesis. Protein  
concentrations of different samples were determined  
at the same time by BCA assay (Pierce) using BSA as  
25        the standard.

Results showed that fraction I (AP) and  
Onconase (AlfaCell) exhibited identical RNase  
activities. Fraction II (AP) and fraction III (AP)  
also exhibited RNase activity, but at a lower  
30        potency, indicating that these fractions comprise  
rOnconase that has not refolded properly. The  
activity in the fractions II (AP) and III (AP)  
likely was a spill over from fraction I (AP).

Fraction I (negative control) exhibited substantially lower activity than fraction I (AP). Addition of an excess of aminopeptidase to the translation system did not change the results, demonstrating that the lower activity of fraction I as compared to fraction I (AP) was not due to incomplete removal of aminopeptidase following removal of the N-terminal Met, and that it was the N-terminal Met that was inhibiting RNase activity.

The ability of rOnconase to inhibit protein synthesis by three B-lymphoma cell lines, Daudi, Raji, and CA-46, and a human T cell line, Hut 102 also was assessed. Cells were plated at concentrations of  $2 \times 10^5$  cells/ml in 96-well microtiter plates overnight in the appropriate complete media. The complete media were replaced by serum-free and leucine-free media containing increasing concentrations of rOnconase and rOnconase immunotoxin, both recombinantly-produced and chemically-conjugated, for 16 hours followed by a 1 hour pulse with 0.1  $\mu$ Ci of [ $^{14}$ C]leucine. Cells were harvested onto glass fiber filters using a cell harvester (Skaron), washed with water, dried with ethanol, and counted. Cytotoxic/cytostatic effects on the cells were assessed by a method that differed only in that a 1 hour pulse with 0.5  $\mu$ Ci of [ $^3$ H]thymidine was used.

The results showed that rOnconase and recombinantly-produced and chemically-conjugated rOnconase immunotoxins all inhibited protein synthesis ( $IC_{50}$  of 10-100 pM) and produced cytotoxic/cytostatic effects in human lymphoma cells. The *in vitro* cytotoxicity of the



immunoconjugate was enhanced to  $IC_{50}$  0.9 pM by monensin. By comparison, conjugates of LL2 with either EDN (eosinophil RNase) or pancreatic RNase A (hpanc) were considerably less cytotoxic, with  $IC_{50}$  of hLL2-EDN of 70 nM and that of hLL2-hpanc greater than 50 nM, respectively. The cytotoxicity of LL-2 conjugates versus their component proteins are summarized in Table 1.

Table 1

	$IC_{50}$ (pM)			
	LL2-rOnconase	rOnconase	LL2	LL2-EDN
Daudi	50-500	>200,000	>23,000	>43,000
CA-46	800	>200,000	>23,000	>43,000
Raji	800	>200,000	>23,000	
Hut-102	>40,000	37,000		

Conjugates of hLL2-rOnconase display similar results with an  $IC_{50}$  of 400-500 pM when tested on Daudi cells.

Example 10: In vivo activity of rOnconase and rOnconase immunotoxins

SCID mice with minimal disease and with more advanced Daudi lymphoma were treated with LL2-rOnconase (100  $\mu$ g QD x5). The mice exhibited increased life span of 216% and 135%, respectively.

While the invention has been described in detail with respect to particular preferred embodiments, it should be understood that such description is presented by way of illustration and not limitation. Many changes and modifications within the scope of the present invention may be made without departing from the spirit thereof, and the invention includes all such modifications.

What is claimed is:

1. An Onconase molecule which has pyroglutamate as the N-terminal residue, wherein said Onconase molecule is recombinantly-produced in *E. coli*.

2. A recombinantly-produced Onconase molecule according to claim 1, which has the sequence and structure of Onconase purified from *Rana pipiens*.

3. A fusion protein comprising a recombinantly-produced Onconase molecule according to claim 1 fused to a targeting moiety.

4. A fusion protein according to claim 3, wherein a nucleic acid sequence encoding Onconase and a targeting moiety is expressed recombinantly.

5. A fusion protein according to claim 3, wherein the targeting moiety is one of an antibody, antibody fragment, cytokine and growth receptor.

6. A fusion protein according to claim 3, wherein the targeting moiety is a  $F(ab')_2$ ,  $F(ab)_2$ ,  $Fab'$ ,  $Fab$ , or  $Fv$  antibody fragment.

7. A conjugate comprising a recombinantly-produced Onconase molecule according to claim 1, chemically coupled to a targeting moiety in a covalent linkage.

8. A composition comprising recombinantly-produced Onconase according to claim 1, and a pharmaceutically acceptable carrier.

9. A composition comprising a fusion protein according to claim 3, and a pharmaceutically acceptable carrier.

10. A composition comprising a conjugate according to claim 7, and a pharmaceutically acceptable carrier.

11. A method of treatment for cancer, comprising administering to a subject in need of such treatment a therapeutically effective amount of a recombinantly-produced Onconase according to claim 1.

12. A method of treatment for cancer, comprising administering to a subject in need of such treatment a therapeutically effective amount of a fusion protein according to claim 3.

13. A method of treatment for cancer, comprising administering to a subject in need of such treatment a therapeutically effective amount of a conjugate according to claim 7.

14. A method according to claim 12, wherein said cancer is selected from the group consisting of colon cancer and pancreatic cancer.

15. A method according to claim 13, wherein said cancer is selected from the group consisting of colon cancer and pancreatic cancer.

16. A fusion protein according to claim 3, wherein the targeting moiety is an antibody or antibody fragment to a glycosylated cell surface antigen that is expressed on a solid tumor.

17. A fusion protein according to claim 16, wherein said glycosylated antigen is carcinoembryonic antigen.

18. A conjugate according to claim 7, wherein the targeting moiety is an antibody or antibody fragment to a glycosylated cell surface antigen that is expressed on a solid tumor.

19. A conjugate according to claim 18, wherein said glycosylated antigen is carcinoembryonic antigen.

Figure 1

50  
ATGCAGGATT GGCTAACGTT TCAGAAGAAA CATATCACGA ATACACGAGA  
TACGTCCTAA CCGATTTCGAA AGTCTTCTTT GTATAGTGCT TATCTGCTCT  
M Q D W L T F Q K K H I T N T K D

100  
TGTAAGGATA  
TGTAGACTGC GACAATATAA TGTCTACGAA TCTGTTTCAC TGTAAGGATA  
ACATCTGACG CTGTTATATT ACAGATGCTT AGACAAAGTG ACATTCCTAT  
V D C D N I M S T N L F H C K D

150  
AGAATACCTT TATATACAGT CGGCCAGAGC CTGTAAAGGC TATCTGTAAA  
TCTTATGGAA ATATATGTCA GCCGGTCTCG GACATTTCCG ATAGACATTT  
K N T F I Y S R P E P V K A I C K

200  
GGCATTATCG CGAGTAAGAA CGTGCTGACT ACTTCCGAGT TCTATCTGTC  
CCGTAATAGC GCTCATTCTT GCACGACTGA TGAAGGCTCA AGATAGACAG  
G I I A S K N V L T T S E F Y L S

250  
CGATTGCAAT GTGACTTCAC GGCCCTGCAA ATATAAGCTG AAGAAAAGCA  
GCTAACGTTA CACTGAAGTG CCGGGACGTT TATATTCGAC TTCTTTTCGT  
D C N V T S R P C K Y K L K K S

300  
CTAACAAATT TTGCGTAACT TGCGAGAACC AGGCTCCTGT ACATTTTCGTT  
GATTGTTTAA AACGCATTGA ACGCTCTTGG TCCGAGGACA TGTAAGCAA  
T N K F C V T C E N Q A P V H F V

GGAGTCGGGA GCTGCTAA  
CCTACGCCCT CGACGATT  
G V G S C \*

# INTERNATIONAL SEARCH REPORT

Int .tional Application No

PCT/US 99/04252

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/55 C12N9/22 C12N15/62 C07K19/00 C07K16/46  
A61K38/46

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 38112 A (THE UNITED STATES OF AMERICA) 16 October 1997 (1997-10-16) page 2, line 4 - line 22 page 2, line 31 - page 3, line 22 page 9, line 23 - page 13, line 9; examples I-III ---	1-19
X	WO 97 31116 A (THE GOVERNMENT OF THE UNITED STATES OF AMERICA) 28 August 1997 (1997-08-28) cited in the application page 3, line 10 - page 4, line 13 page 6, line 24 - page 9, paragraph 2; examples see sequence listing SEQ ID NO:1 --- -/--	1-19



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

13 July 1999

Date of mailing of the international search report

22/07/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 91 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Montero Lopez, B

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/04252

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WOJCIECH ARDELT ET AL.: "Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos " JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 1, 5 January 1991 (1991-01-05), pages 245-251, XP000172527 MD US abstract; figure 1 ---	1,2,8,11
X	ESTER BOIX ET AL.: "Role of the N terminus in RNase A homologues: differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity" JOURNAL OF MOLECULAR BIOLOGY, vol. 257, no. 5, 19 April 1996 (1996-04-19), pages 992-1007, XP000675661 abstract page 993, right-hand column, paragraph 2 page 993, right-hand column, last paragraph - page 997, left-hand column, paragraph 1 ---	1,2,8
P,X	WO 98 50435 A (THE GOVERNMENT OF THE UNITED STATES OF AMERICA) 12 November 1998 (1998-11-12) page 5, line 17 - page 6, line 2 page 9, line 1 - line 10 page 11, line 1 - line 20 page 16, line 19 - page 20, line 3; examples ---	1-19
P,X	LEUNG, S.O. ET AL. : "Recombinant expression of ribonuclease of Rana pipien origin" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 40, March 1999 (1999-03), pages 353-354, XP002105912 see abstract no. #2341 -----	1-5,7, 16-19



# INTERNATIONAL SEARCH REPORT

international application No.

PCT/US 99/ 04252

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 11-15  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

In: International Application No

PCT/US 99/04252

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9738112 A	16-10-1997	AU 2442697 A	29-10-1997
WO 9731116 A	28-08-1997	AU 2130697 A	10-09-1997
		CA 2245804 A	28-08-1997
		CN 1212016 A	24-03-1999
		EP 0896625 A	17-02-1999
WO 9850435 A	12-11-1998	AU 7280398 A	27-11-1998